Outcome of Fungal Infection in Patients Undergoing Myelosuppressive Chemotherapy in a Tertiary Care Centre During 12 Years (1995-2006).

Marie von Lilienfeld-Toal, MD*,1, Axel Glasmacher, MD2, Günter Marklein, MD*,1, Peter Brossart, MD3 and Corinna Hahn-Ast, PhD*,1

Author address: 

1 University of Bonn, Bonn, Germany, 2 Celgene GmbH, München, Germany, 3 Hem./Onc., Univ. of Bonn, Bonn, Germany


Poster Board I-406 Invasive fungal infections (IFI) contribute significantly to mortality and morbidity in patients receiving myelosuppressive chemotherapy for hematological malignancies. The present study evaluates the incidence of IFI, the overall survival (OS), the infection-related mortality and changes in treatment of IFI in our department from 1995 until 2006. Data of all consecutive chemotherapy courses were retrospectively collected with a standard questionnaire. EORTC/MSG criteria for IFI were applied with a modification: A positive PCR-result for Aspergillus spp. in bronchoalveolar lavage was also defined as probable IFI. In total, 1693 courses of 592 patients were evaluated. Sixty-three percent were given to treat acute myeloid leukemia, the rest for acute lymphoblastic leukemia or aggressive lymphoma. IFI were observed in 139/592 patients (23%, 95% confidence interval (CI) 20-27%), and in 149/1693 (8.8%, 95%CI 8-10%) courses. IFI-related mortality was 57% in 1995-2001 and 29% in 2002-2006, p

abstract No: 


Full conference title: 

51st American Society of Haematologists Annual Meeting
    • ASH 51st (2009)